Inventor · disambiguated record
Hilmar Erhard Ebersbach
Also filed as: EBERSBACH HILMAR · EBERSBACH HILMAR ERHARD
12 granted patents·9 pending applications·219 citations·filing 2007–2025
90Inventor score
Top patents by PatentIndex Score
21 records- 0197US10174095B2Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Jan 8, 2019·41 cites·50 claims
- 0297US9777061B2Treatment of cancer using a CD33 chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Oct 3, 2017·85 cites·24 claims
- 0395US11084880B2Anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Aug 10, 2021·15 cites·24 claims
- 0493US7838629B2Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatographySCIL PROTEINS GMBH·Filed 2007·Granted Nov 23, 2010·71 cites·34 claims
- 0585US10568947B2Treatment of cancer using a CLL-1 chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Feb 25, 2020·6 cites·38 claims
- 0682US10851166B2Treatment of cancer using a CD33 chimeric antigen receptorNOVARTIS AG·Filed 2017·Granted Dec 1, 2020·1 cites·22 claims
- 0779US2025353916A1Treatment of cancer using a cd33 chimeric antigen receptorNOVARTIS AG·Filed 2025·Application pending·0 cites
- 0870US12214037B2Treatment of cancer using humanized anti-BCMA chimeric antigen receptorUNIV PENNSYLVANIA·Filed 2021·Granted Feb 4, 2025·0 cites·16 claims
- 0970US2023052970A1Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1069US12338287B2Treatment of cancer using a CD33 chimeric antigen receptorNOVARTIS AG·Filed 2020·Granted Jun 24, 2025·0 cites·24 claims
- 1168US2025179447A1Solubilized apyrases, methods and useNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1265US2020215171A1Treatment of cancer using a cll-1 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1364US12325870B2Solubilized apyrases, methods and useNOVARTIS AG·Filed 2019·Granted Jun 10, 2025·0 cites·8 claims
- 1462US2025353883A1Novel recombinant aav vp2 fusion polypeptidesNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1554US11459390B2Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptorNOVARTIS AG·Filed 2016·Granted Oct 4, 2022·0 cites·21 claims
- 1654US10919955B2Rodent combinatorial antibody librariesMORPHOSYS AG·Filed 2017·Granted Feb 16, 2021·0 cites·18 claims
- 1753US2014161796A1Single chain proteins with c-terminal modificationsLOEW ANDREAS·Filed 2013·Application pending·0 cites
- 1853US2018106790A1Single chain proteins with c-terminal modificationsNOVARTIS AG·Filed 2017·Application pending·0 cites
- 1952US2022348632A1Nkg2d fusion proteins and uses thereofNOVARTIS AG·Filed 2020·Application pending·0 cites
- 2047US9650432B2Rodent combinatorial antibody librariesPRASSLER JOSEF·Filed 2011·Granted May 16, 2017·0 cites·24 claims
- 2139US2021198368A1Multispecific molecules targeting cll-1NOVARTIS AG·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hilmar Erhard Ebersbach files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →